{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:34:12Z","timestamp":1781782452639,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Children Cancer Research Foundation"},{"DOI":"10.13039\/100000902","name":"Pediatric Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000902","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paul Luisi Foundation"},{"name":"Marisa Fund"},{"name":"Pediatric Academic Society"},{"name":"Ashley G Foundation"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jcyt.2014.03.008","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T11:46:47Z","timestamp":1400586407000},"page":"1431-1440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity"],"prefix":"10.1016","volume":"16","author":[{"given":"Prakash","family":"Satwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Bavishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ayello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmella","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaya","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2014.03.008_bib1","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","volume":"30","author":"Cairo","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib3","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2007.10.7508","article-title":"Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952","volume":"25","author":"Malempati","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcyt.2014.03.008_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.12.713","article-title":"National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee","volume":"17","author":"Bishop","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2014.03.008_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjh.12239","article-title":"Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission","volume":"161","author":"Hochberg","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/83130","article-title":"On guard: activating NK cell receptors","volume":"2","author":"Lanier","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2014.03.008_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2014.03.008_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/85321","article-title":"Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells","volume":"2","author":"Groh","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib12","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1073\/pnas.032668099","article-title":"Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the\u00a0MHC class I-related molecule MICA","volume":"99","author":"Tieng","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2014.03.008_bib13","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1073\/pnas.201238598","article-title":"Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo","volume":"98","author":"Cerwenka","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2014.03.008_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/35093109","article-title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity","volume":"413","author":"Diefenbach","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2014.03.008_bib15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/nm1101-1178","article-title":"A\u00a0renaissance for the tumor immunosurveillance hypothesis","volume":"7","author":"Lanier","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2014.03.008_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni1350","article-title":"Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity","volume":"7","author":"Groh","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2014.03.008_bib18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00262-006-0167-1","article-title":"Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA","volume":"55","author":"Holdenrieder","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2014.03.008_bib19","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.4049\/jimmunol.169.8.4098","article-title":"Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding","volume":"169","author":"Salih","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib20","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1158\/0008-5472.CAN-07-6768","article-title":"Tumor-associated MICA is shed by ADAM proteases","volume":"68","author":"Waldhauer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2014.03.008_bib21","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2014.03.008_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/07357900600814979","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"24","author":"Fouladi","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jcyt.2014.03.008_bib24","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jcyt.2014.03.008_bib25","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2014.03.008_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1158\/1078-0432.CCR-05-1225","article-title":"Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo","volume":"12","author":"Graham","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2014.03.008_bib27","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","article-title":"Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report","volume":"24","author":"Fouladi","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2005.05592.x","article-title":"Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function","volume":"130","author":"Satwani","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3109\/14653249.2011.563292","article-title":"Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function","volume":"13","author":"Satwani","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2014.03.008_bib30","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2014.03.008_bib31","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.exphem.2009.07.009","article-title":"Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy","volume":"37","author":"Ayello","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib32","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2005-09-3904","article-title":"Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy","volume":"107","author":"Serrano","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Bruserud","year":"2007","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2014.03.008_bib35","first-page":"371832","article-title":"Physical and functional HAT\/HDAC interplay regulates protein acetylation balance","volume":"2011","author":"Peserico","year":"2011","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/leu.2008.354","article-title":"Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate","volume":"23","author":"Poggi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2014.03.008_bib37","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2002-02-0350","article-title":"Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect","volume":"100","author":"Farag","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.V96.1.24","article-title":"Biological and therapeutic aspects of infant leukemia","volume":"96","author":"Biondi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.leu.2402595","article-title":"Infant acute lymphoblastic leukemia: combined cytogenetic, immunophenotypical and molecular analysis of 77 cases","volume":"16","author":"Borkhardt","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2014.03.008_bib40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"Dordelmann","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib41","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.leu.2404577","article-title":"Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: the \u2018big sister\u2019 of the infant disease?","volume":"21","author":"Mann","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2014.03.008_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A\u00a0treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2014.03.008_bib43","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/pbc.21352","article-title":"Acute lymphoblastic leukemia in infancy","volume":"49","author":"Silverman","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jcyt.2014.03.008_bib44","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.03.008_bib45","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/pbc.21975","article-title":"Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: a report from the Japan Infant Leukemia Study Group","volume":"52","author":"Tomizawa","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jcyt.2014.03.008_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbmt.2010.03.002","volume":"16","author":"Cairo","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2014.03.008_bib47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-010-1099-6","article-title":"MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)","volume":"90","author":"Burbury","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2014.03.008_bib48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.23112","article-title":"The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients","volume":"87","author":"Kelly-Sell","year":"2012","journal-title":"Am J Hematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324914005489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324914005489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:20:22Z","timestamp":1761430822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324914005489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1465324914005489"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2014.03.008","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2014.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}